We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


DNA Aptamer Can Determine Stem Cells Lineage During Differentiation

A graphic showing how an anti-nucleolin DNA aptamer, iSN04, regulates cardiomyogenesis of murine pluripotent stem cells.
Credit: Tomohide Takaya from Shinshu University, Japan.
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 3 minutes


Japanese researchers discover iSN04, a DNA aptamer, guiding stem cell differentiation into cardiomyocytes, offering economical potential for regenerative medicine and personalized therapies.

Key takeaways

  • Researchers in Japan have identified an anti-nucleolin DNA aptamer, iSN04, which can guide stem cell differentiation, particularly towards cardiomyocytes, offering potential in regenerative medicine.

    • Induced pluripotent stem cells (iPSCs) are valuable for regenerative therapies, but generating specific cell types is complex and costly. iSN04 may streamline this process economically.

      • The study demonstrates iSN04's ability to induce cardiomyocyte differentiation from iPSCs by modulating nucleolin protein and the Wnt signaling pathway, potentially revolutionizing regenerative medicine and personalized therapies.

          Guiding induced pluripotent stem cells

          Generating specific cell lineages from induced pluripotent stem cells and embryonic stem cells is the holy grail of regenerative medicine. Guiding iPSCs toward a target cell line has garnered much attention, but the process remains challenging. Now, researchers from Japan have discovered that an anti-nucleolin DNA aptamer, iSN04, can determine a cell’s lineage during differentiation. By demonstrating the generation of cardiomyocytes from murine pluripotent stem cells, their concept shows promise as a regenerative therapy.

          Self-renewal and pluripotency–the capacity to form any cell lineage–are inherent characteristics of induced pluripotent stem cells (iPSCs). Furthermore, they are highly prized in regenerative therapies targeting cardiovascular, neurological, and metabolic diseases as they are immunologically suitable for transplantation back into a donor. Unfortunately, regenerative medicine is not yet feasible outside a laboratory setting as available protocols to generate target cells are complicated and expensive. This raises a pertinent question: Can regulating the fate of stem cells in clinical settings and at scale be made more economical?

          Want more breaking news?

          Subscribe to Technology Networks’ daily newsletter, delivering breaking science news straight to your inbox every day.

          Subscribe for FREE

          A team of researchers from Shinshu University, the National Institute of Advanced Industrial Science and Technology, and the University of Shizuoka in Japan set out to address this question by leveraging nucleic acid aptamers. Aptamers are single-stranded pieces of DNA that bind to target proteins and are able to modulate signaling cascades during cell differentiation when a stem cell commits to a specific functional role or phenotype. They hold promise in regenerative medicine as they are easily modified, can be synthesized economically, and are suitable for long-term storage.

          The team, led by Associate Professor Tomohide Takaya from the Department of Agricultural and Life Sciences at Shinshu University, recently discovered that an anti-nucleolin aptamer, myogenetic oligodeoxynucleotide iSN04, induced myocardial differentiation in embryonic stem cells (ESCs). The study was led by Mina Ishioka, a graduate student in Dr. Takaya’s laboratory, and published in The International Journal of Molecular Sciences on 21 September 2023.

          “We had previously found that iSN04 promoted myogenic precursor cells (myoblasts) to differentiate into skeletal muscle cells and had hypothesized that the aptamer also enhanced differentiation of pluripotent stem cells. We were intrigued by the prospect of using iSN04 to promote iPSC differentiation into cardiomyocytes as this could lead to regenerating heart tissue,” says Dr. Takaya, elaborating on the team’s motivation to pursue the research.

          Using various assays like RNA sequencing, cell staining and imaging, and molecular interaction and pathway analysis, the researchers investigated iSN04’s effect on murine ESCs and iPSCs. iSN04 treatment under differentiating conditions inhibited stem cell commitment to the cardiac lineage. However, when these pluripotent stem cells were treated after experiencing differentiating conditions for five days, specific marker genes were upregulated, and the cells committed to forming beating cardiomyocytes.

          “Ours is the first report to a DNA aptamer that allows cardiomyocytes to develop from iPSCs,” explains Dr. Takaya when asked about the significance of the work. “We uncovered two mechanisms of nucleolin interference with iSN04 at play whereby early treatment inhibits cardiomyogenesis, while treatment at a later stage enhances the generation of cardiac progenitors. First, iSN04 governs the translocation of nucleolin protein between the cytoplasm, plasma membrane, and nucleus. Second, it results in the modulation of the Wnt signaling pathway that governs cell differentiation.

          The immunostaining experiments revealed that nucleolin was retained in the nucleoli following iSN04 treatment. Nucleolar nucleolin has a role in chromatin remodeling and gene transcription, and interestingly enough, Wnt pathway genes were differentially expressed in the RNA-seq data following iSN04 suppression. The team postulates that the iSN04-anchored nucleolin alters gene expression and Wnt signaling. Ultimately, terminal cell differentiation commits to the cardiomyocyte lineage.

          And how could these findings impact regenerative medicine and patients’ lives in the long term? Dr. Takaya provides insights into the broader implications of their work. “We believe there is a strong case to be made for further studies evaluating DNA aptamers in regenerative medicine. Aptamers are cost-effective and open up the possibility of producing specific cells from the patient’s stem cells. But it doesn’t end there! Since the aptamers can regulate stem cell fate, they can serve as therapeutic agents for many conditions linked to stem cell dysfunction,” he concludes.

          Reference: Ishioka M, Nihashi Y, Sunagawa Y, et al. Myogenetic oligodeoxynucleotide induces myocardial differentiation of murine pluripotent stem cells. IJMS. 2023;24(18):14380. doi: 10.3390/ijms241814380

          This article has been republished from the following materials. Article summaries may have been generated by fact-checked AI models. Note: material may have been edited for length and content. For further information, please contact the cited source.